Texas Bets Big on Ibogaine as Brain Health's New Frontier

AUSTIN, TX – April 17, 2026 – In a move that solidifies Texas as the unlikely epicenter of psychedelic medicine innovation, Beond Inc., the world's most experienced provider of ibogaine treatments, announced today it is establishing its U.S. headquarters in Austin. The decision plants a flag for the U.S.-based company, whose clinical operations are in Cancún, Mexico, squarely in the state that is betting millions on the therapeutic potential of the powerful, controversial psychedelic.

The announcement comes at a pivotal moment. Just yesterday, the White House signaled a major shift in federal posture, with President Trump signing an executive order to accelerate research into psychedelic therapies, specifically earmarking $50 million for ibogaine studies. This national momentum converges with Texas's own trailblazing efforts, creating a powerful current that companies like Beond hope to ride into the mainstream of American healthcare.

Texas's $50 Million Gamble on Brain Health

Texas is aggressively positioning itself not just as a participant, but as a leader in the future of neuroplasticity medicine. The state legislature, in a landmark 2025 session, committed a staggering $50 million in public funds to advance ibogaine through FDA-approved clinical trials. This initiative, the largest of its kind in U.S. history, aims to tackle the state's pressing mental health crises, particularly among its veteran population.

Driving this charge is a bipartisan coalition of policymakers and advocates, including former Governor Rick Perry and State Representative Cody Harris (R–Palestine), who authored the historic legislation. Their advocacy is fueled by compelling, albeit early, data and the desperate need for more effective treatments for conditions like PTSD, traumatic brain injury (TBI), and opioid addiction.

“In Texas, we take care of our own, and right now, too many veterans and families are still searching for answers,” said Rep. Harris in a statement. “We owe it to them to follow the science and take a serious look at options like ibogaine - not as hype, but as a potential path forward if it’s approached the right way. Texas is building the kind of ecosystem that can do that responsibly.”

The state's program, now spearheaded by UTHealth Houston, is known as IMPACT (Ibogaine for Mental and Physical Health After Combat Trauma). Its mission is clear: to generate rigorous scientific data under Texas leadership, with the state retaining intellectual property rights and a share of future revenue should a treatment be successfully commercialized.

A Bridge from Cancún to the U.S. Market

Into this burgeoning ecosystem steps Beond, a company that has spent years operating where the U.S. cannot. While ibogaine remains a Schedule I controlled substance domestically—deemed to have no accepted medical use—Beond has conducted thousands of medically supervised treatments at its licensed facility in Cancún. The company now aims to bring that operational experience to bear on the developing U.S. landscape.

“Texas is the center of gravity for the future of neuroplastogen medicine, particularly ibogaine,” said Tom Feegel, co-founder and CEO of Beond. “It's critical that organizations with real clinical experience are part of that conversation.”

Crucially, the Austin headquarters will not be a treatment center. Ibogaine will not be administered there. Instead, the office will function as a strategic hub for research, data infrastructure, and the development of pre-treatment preparation and post-treatment integration programs for U.S. clients who travel to Mexico. It represents a bet that the most valuable commodity in this new field will be expertise.

“What we've learned from thousands of treatments is that when you address the underlying neurobiology and actually give the brain the conditions it needs to reorganize, people are afforded real, long lasting positive change,” stated Talia Eisenberg, Beond’s co-founder. The company's goal, she explained, is to “architect and optimize the end-to-end experience,” setting a U.S. standard for safety and efficacy.

While Beond touts the “largest real-world data set” in the field, this information has largely been gathered outside the purview of the FDA and has not yet been extensively published in peer-reviewed scientific journals, a critical step for gaining acceptance within the broader U.S. medical establishment.

The Promise and Peril of a Powerful Psychedelic

Ibogaine’s journey toward legitimacy is fraught with both immense promise and significant peril. Advocates point to a growing body of evidence suggesting its remarkable efficacy. Observational studies and early trials, including a landmark Stanford University study on retired Navy SEALs, have shown dramatic improvements in symptoms of PTSD, depression, anxiety, and addiction. Some reports indicate ibogaine can eliminate up to 80% of opioid withdrawal symptoms and significantly reduce cravings for months.

However, the substance carries severe risks that cannot be ignored. The most significant danger is cardiotoxicity. Ibogaine is known to prolong the QT interval in heart rhythms, which can lead to fatal cardiac arrhythmias, even in healthy individuals. This risk has been linked to a number of deaths, most often in settings without rigorous medical screening and monitoring.

Other potential side effects include intense and sometimes disturbing psychological experiences, neurological issues like tremors and confusion, and severe gastrointestinal distress. Its classification as a Schedule I drug places it in the same category as heroin, reflecting deep-seated federal concerns about its safety and potential for abuse. This legal status stands in stark contrast to the growing political and scientific momentum to explore its benefits.

A New National Momentum

The landscape is shifting rapidly. The White House executive order signed yesterday adds federal firepower to state-level efforts, directing the FDA to expedite reviews and injecting an additional $50 million into research. While the order does not re-schedule the drug, it signals a clear intent to seriously investigate its potential, particularly for veterans.

Beond is entering a U.S. research field that, while nascent, is not empty. DemeRx Inc. is already proceeding through Phase II/III FDA trials with an ibogaine derivative designed to be safer for the heart. Academic powerhouses like Stanford and Johns Hopkins are actively studying the mechanisms of psychedelics, and other companies are exploring novel ways to synthesize the complex molecule.

This convergence of state funding, federal interest, private enterprise, and academic research is creating a unique environment in Austin. Beond's strategy is to leverage its extensive clinical experience from Mexico to influence how ibogaine-assisted care is built, delivered, and scaled in the United States. The Austin headquarters will focus on recruiting top talent in clinical medicine, hospitality, and AI-driven data systems to build the infrastructure for a future U.S. market.

As Beond plants its flag in Texas soil, it is betting that its years of hands-on practice can shape the future of American mental healthcare. Whether this deep operational experience can successfully navigate the rigorous gauntlet of U.S. regulation and scientific validation will ultimately determine if ibogaine’s American moment has truly arrived.